Rain Oncology Inc
Change company Symbol lookup
Select an option...
RAIN Rain Oncology Inc
MA Mastercard Inc
WDBG Neuro-Hitech Inc
GLRY Inspire Faithward Mid Cap Momentum ETF
WCC Wesco International Inc
TNP-F Tsakos Energy Navigation Ltd
ANEB Anebulo Pharmaceuticals Inc
NCA Nuveen California Municipal Value Fund
SGOL abrdn Physical Gold Shares ETF
GAB-K Gabelli Equity Trust Inc
Go

Health Care : Pharmaceuticals |
Company profile

Rain Oncology Inc., formerly Rain Therapeutics Inc., is a late-stage precision oncology company. The Company is focused on developing therapies that target oncogenic drivers to genetically select patients. The Company’s product candidates include milademetan and RAD52. Its milademetan is an oral small molecule, an inhibitor of mouse double minute 2 (MDM2) is being developed in patients with wildtype tumor protein 53 (p53) cancers that are also exhibiting MDM2 dependence. MDM2 dependence may be occurring either through MDM2 gene amplification, protein overexpression, loss of an MDM2 regulator, or other mechanisms. RAD52 is focused on the DNA Damage Response (DDR) pathway. RAD52 represents a strategy for patients that may exhibit homologous recombination deficiencies (HRD+), or a loss of function, of several pathway constituents, including BRCA1/2, PALB2, or several others in tumor types frequently characterized by these deficiencies.

Postmarket

Last Trade
Delayed
$8.28
-0.17 (-2.01%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$8.45
Day's Change
-0.01 (-0.12%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
8.78
Day's Low
8.36
Volume
(Light)
Volume:
69,771

10-day average volume:
223,522
69,771
Latest Earnings Missed Consensus (Q4 ending 12/2022)Next Earnings Announcement
Q4
Announced March 9, 2023
-$0.70Q4 Consensus
of 8 analysts
-$0.56Difference from
consensus
-25.22%
Q1 Earnings
will announce
(Unconfirmed) May 2, 2023

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

RAIN's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.